Over 1,000 Cardiac Patients Treated with Genesis Robotic System
Genesis RMN, the latest innovation in Stereotaxis’ robotic technology, was first used in late 2020 following regulatory clearances in
The Genesis RMN system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Physicians have used Genesis RMN to treat a broad spectrum of arrhythmia patients, including the underserved community of patients with complex cardiac disease that cannot be treated well or at all without Stereotaxis’ robotic technology.
“We are pleased to celebrate the pioneering physicians and hospitals that demonstrated the clinical value of Genesis RMN for patients, physicians, and health systems through robust regular use,” said
About
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability or willingness of customers to purchase its technology, competitive factors, changes in healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the
Stereotaxis Contacts:
Chairman and Chief Executive Officer
Chief Financial Officer
314-678-6100
investors@stereotaxis.com

Source: Stereotaxis, Inc.